Artificial heart developer Carmat could receive up to €17.5M in funding

The Aeson artificial heart. [Image from Carmat’s website]Carmat announced today that the European Council selected it to join its EIC Accelerator program for innovative companies in Europe.

The total funding could reach €17.5 million ($18.6 million).

Paris-based Carmat develops a total artificial heart. It designed the platform to provide a therapeutic alternative for those suffering from end-stage biventricular heart failure.

EIC Accelerator funds European companies aiming to bring innovations to market. The council selected Carmat and its Aeson artificial heart, recognizing it as a “high-quality medical innovation,” according to a news release.

As a result of the selection, Carmat received the maximum possible funding available. It picked up a non-dilutive grant of €2.5 million ($2.7 million) to support the industrialization of Aeson. Additionally, Carmat received an optional equity financing of €15 million ($15.9 million). This f…

Read more
  • 0